Abbott Cuts Guidance After Exact Sciences Split

Abbott Laboratories shares came under sharp selling pressure following the company's updated guidance issued after its decision to dissolve a partnership or agreement connected to Exact Sciences. The guidance revision spooked investors, triggering a notable decline in the stock. Abbott, a diversified medical device and diagnostics giant, had maintained ties with Exact Sciences, a molecular diagnostics company best known for its Cologuard colorectal cancer screening test. The severance of that relationship appears to have prompted Abbott to reset its financial outlook, which fell short of market expectations. The mechanism is straightforward: losing a commercial or revenue-sharing arrangement with a diagnostics partner reduces near-term revenue visibility, forcing a downward adjustment to forward estimates. Analysts and institutional investors, already scrutinizing Abbott's diagnostics segment following the post-pandemic normalization of COVID testing revenue, now face added uncertainty around the company's growth trajectory. Investors should watch for any updated segment disclosures, analyst estimate revisions, and whether Abbott pursues alternative diagnostics partnerships to offset the commercial gap left by the Exact Sciences split.